Eli Lilly Revenue Down, But Still Beats Consensus

BMI View: Despite Eli Lilly's sales continuing to fall during Q212, primarily owing to the patent expiration of Zyprexa (olanzapine), its attractiveness to investors has increased. This is because the top-line revenue figure has surpassed consensus expectations and its fundamental financial performance was well above the industry average. BMI believes the company's future growth relies on the evolution of its product pipeline and on it increasing its emerging market presence.

To read the full article, please choose one of the following options: